Xenon Pharmaceuticals Inc. (XENE) financials: revenue, earnings and cash flow
Fiscal 2016–2025 · from SEC filings · data as of November 13, 2026
Summary
Xenon Pharmaceuticals’s revenue went from $2M in fiscal 2016 to $8M in fiscal 2025, growth of about 17.2% a year.
Net income in fiscal 2025 was -$346M, a net margin of -4612.1%; the best year in this period was 2016 with -$23M.
Free cash flow was -$280M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 412% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $0 | $0 | $9M | $18M | $32M | $7M | — | $311000 | $2M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$373M | -$279M | -$214M | -$129M | -$79M | -$31M | -$43M | -$38M | -$33M | -$25M |
| Net income | -$346M | -$234M | -$182M | -$125M | -$79M | -$29M | -$42M | -$34M | -$31M | -$23M |
| EPS (diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | $-1.54 | $-1.63 | $-1.72 | $-1.48 |
| R&D | $301M | $210M | $168M | $106M | $75M | $51M | $39M | $24M | $26M | $20M |
| Revenue growth | — | — | −100.0% | −48.8% | −42.7% | +371.0% | — | — | −82.8% | −88.4% |
Cash flow
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$279M | -$181M | -$151M | -$101M | -$70M | -$48M | -$5M | -$35M | -$29M | -$20M |
| Capital spending | -$799000 | -$3M | -$6M | -$3M | -$2M | -$3M | -$1M | -$507000 | -$315000 | -$279000 |
| Free cash flow | -$280M | -$184M | -$157M | -$104M | -$72M | -$51M | -$6M | -$35M | -$29M | -$20M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $54M | $51M | $32M | $20M | $10M | $6M | $3M | $3M | $2M | $2M |
Balance sheet
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | $549M | $627M | $638M | $592M | $552M | $177M | $141M | $119M | $44M | $64M |
| Debt | $8M | $9M | $11M | $10M | $8M | $3M | $16M | $16M | $7M | — |
| Equity | $582M | $755M | $928M | $721M | $550M | $171M | $92M | $103M | $36M | $64M |
| Total assets | $633M | $798M | $965M | $754M | $572M | $189M | $148M | $122M | $46M | $67M |
| Shares (diluted) | 79M | 78M | 67M | 61M | 44M | 35M | 26M | 19M | 18M | 15M |
Margins and returns
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -4974.3% | — | — | -1368.9% | -428.5% | -97.3% | -627.0% | — | -10474.3% | -1376.4% |
| Net margin | -4612.1% | — | — | -1329.0% | -427.9% | -89.6% | -609.1% | — | -9872.7% | -1275.5% |
| FCF margin | -3732.2% | — | — | -1101.6% | -388.1% | -157.8% | -87.2% | — | -9337.9% | -1100.7% |
| ROIC | -50.0% | -35.9% | -22.8% | -13.9% | -14.1% | -17.8% | -39.5% | -32.0% | -59.9% | -30.7% |
| ROE | -59.5% | -31.0% | -19.7% | -17.4% | -14.3% | -16.8% | -45.2% | -33.4% | -85.5% | -36.0% |
Frequently asked questions
What is Xenon Pharmaceuticals’s annual revenue?
$8M in fiscal 2025.
How much profit does Xenon Pharmaceuticals make?
Net income was -$346M in fiscal 2025 (net margin -4612.1%).
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.